Role of TGF-β1 (−509C>T) Promoter Polymorphism in Susceptibility to Cervical Cancer
Abstract:Transforming growth factor-β (TGF-β) family members are multifunctional cytokines that play a key role in cellular growth, proliferation, and differentiation. The aim of study was to evaluate the association of TGF-β1 −509 C>T gene polymorphism with risk of cervical cancer. The study was carried out in 150 histopathology confirmed patients with cervical cancer and 162 cervical-cytology negative females. Polymorphisms for TGF-β1 −509C>T gene was genotyped by polymerase chain reaction and restriction enzyme digestion. Frequencies of individuals with −509TT genotype and T allele of TGF-β1 gene polymorphisms did not differ significantly in patients with cervical cancer and controls (p = 0.328, OR = 1.37 and p = 0.605, OR = 1.09). Cervical cancer patients with −509TT had marginal low risk for stage I (p = 0.04, OR = 0.95, 95% CI = 0.91‐0.99) but −509TT genotype of TGF-β1 was associated with increased risk of stage II of cancer (p = 0.07, OR = 3.13, 95% CI = 0.87‐11.14). In gene‐environment interaction, carriers of TGF-β1 −509TT genotype with tobacco usage were at higher risk of cervical cancer (OR = 3.67, 95% CI = 0.38‐35.1). In conclusion, our data suggest that TGF-β1 −509T allele confers marginal protection for early stage 1B but risk for stage II of cervical cancer.
Document Type: Research Article
Publication date: January 1, 2009
More about this publication?
- Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.